Literature DB >> 30076686

The delta-opioid receptor and Parkinson's disease.

Jin-Zhong Huang1, Yi Ren1, Yuan Xu1, Tao Chen2, Terry C Xia3, Zhuo-Ri Li2, Jian-Nong Zhao2, Fei Hua1, Shi-Ying Sheng1, Ying Xia4,5.   

Abstract

Parkinson's disease (PD) is a common degenerative neurological disease leading to a series of familial, medical, and social problems. Although it is known that the major characteristics of PD pathophysiology are the dysfunction of basal ganglia due to injury/loss of dopaminergic neurons in the substantia nigra pars compacta dopaminergic and exhaustion of corpus striatum dopamine, therapeutic modalities for PD are limited in clinical settings up to date. It is of utmost importance to better understand PD pathophysiology and explore new solutions for this serious neurodegenerative disorder. Our recent work and those of others suggest that the delta-opioid receptor (DOR) is neuroprotective and serves an antiparkinsonism role in the brain. This review summarizes recent progress in this field and explores potential mechanisms for DOR-mediated antiparkinsonism.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  Parkinson’s disease; delta-opioid receptor; dopamine; neurodegeneration; neuroprotection

Mesh:

Substances:

Year:  2018        PMID: 30076686      PMCID: PMC6489828          DOI: 10.1111/cns.13045

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  99 in total

1.  delta-, but not mu- and kappa-, opioid receptor activation protects neocortical neurons from glutamate-induced excitotoxic injury.

Authors:  J Zhang; G G Haddad; Y Xia
Journal:  Brain Res       Date:  2000-12-08       Impact factor: 3.252

2.  Novel δ1-receptor agonist KNT-127 increases the release of dopamine and L-glutamate in the striatum, nucleus accumbens and median pre-frontal cortex.

Authors:  Shunsuke Tanahashi; Yuto Ueda; Akira Nakajima; Satoshi Yamamura; Hiroshi Nagase; Motohiro Okada
Journal:  Neuropharmacology       Date:  2012-01-17       Impact factor: 5.250

3.  δ-Opioid receptors up-regulate excitatory amino acid transporters in mouse astrocytes.

Authors:  Jianfeng Liang; Dongman Chao; Harleen K Sandhu; Yanbing Yu; Li Zhang; Gianfranco Balboni; Dong H Kim; Ying Xia
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

4.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

5.  δ-Opioid receptor activation reduces α-synuclein overexpression and oligomer formation induced by MPP(+) and/or hypoxia.

Authors:  Tao Chen; Jessica Li; Dongman Chao; Harleen K Sandhu; Xiaoping Liao; Jianlong Zhao; Guoqiang Wen; Ying Xia
Journal:  Exp Neurol       Date:  2014-03-05       Impact factor: 5.330

Review 6.  Function of α-synuclein and PINK1 in Lewy body dementia (Review).

Authors:  Akari Minami; Atsuko Nakanishi; Satoru Matsuda; Yasuko Kitagishi; Yasunori Ogura
Journal:  Int J Mol Med       Date:  2014-10-27       Impact factor: 4.101

Review 7.  The many faces of α-synuclein: from structure and toxicity to therapeutic target.

Authors:  Hilal A Lashuel; Cassia R Overk; Abid Oueslati; Eliezer Masliah
Journal:  Nat Rev Neurosci       Date:  2013-01       Impact factor: 34.870

8.  Dopamine and temporal attention: An attentional blink study in Parkinson's disease patients on and off medication.

Authors:  H A Slagter; N C van Wouwe; K Kanoff; R P P P Grasman; D O Claassen; W P M van den Wildenberg; S A Wylie
Journal:  Neuropsychologia       Date:  2016-09-06       Impact factor: 3.139

Review 9.  l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?

Authors:  Elaine Del-Bel; Mariza Bortolanza; Maurício Dos-Santos-Pereira; Keila Bariotto; Rita Raisman-Vozari
Journal:  Synapse       Date:  2016-09-27       Impact factor: 2.562

Review 10.  Parkinson's disease as a result of aging.

Authors:  Manuel Rodriguez; Clara Rodriguez-Sabate; Ingrid Morales; Alberto Sanchez; Magdalena Sabate
Journal:  Aging Cell       Date:  2015-02-09       Impact factor: 9.304

View more
  6 in total

1.  A Critical Role of δ-Opioid Receptor in Anti-microglial Activation Under Stress.

Authors:  Yuan Xu; Feng Zhi; Ya Peng; Jiahao Mao; Gianfranco Balboni; Yilin Yang; Ying Xia
Journal:  Front Aging Neurosci       Date:  2022-05-19       Impact factor: 5.702

Review 2.  The delta-opioid receptor and Parkinson's disease.

Authors:  Jin-Zhong Huang; Yi Ren; Yuan Xu; Tao Chen; Terry C Xia; Zhuo-Ri Li; Jian-Nong Zhao; Fei Hua; Shi-Ying Sheng; Ying Xia
Journal:  CNS Neurosci Ther       Date:  2018-08-03       Impact factor: 5.243

Review 3.  Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson's Disease.

Authors:  Fabio Del Bello; Mario Giannella; Gianfabio Giorgioni; Alessandro Piergentili; Wilma Quaglia
Journal:  Biomolecules       Date:  2019-04-09

Review 4.  Update of inflammasome activation in microglia/macrophage in aging and aging-related disease.

Authors:  Meng-Yan Hu; Yin-Yao Lin; Bing-Jun Zhang; Dan-Li Lu; Zheng-Qi Lu; Wei Cai
Journal:  CNS Neurosci Ther       Date:  2019-11-14       Impact factor: 5.243

5.  Substance Use Disorders in Patients With Parkinson's Disease and Adverse Hospitalization Outcomes: A National Inpatient Study.

Authors:  Jaskaranpreet Kaur; Ramneek K Sandhu; Khadija T Kubra; Johanna S Canenguez Benitez; Henry K Onyeaka; Sabiha Akter; Ozge C Amuk Williams
Journal:  Cureus       Date:  2021-06-29

6.  Delta Opioid Receptor Activation with Delta Opioid Peptide [d-Ala2, d-Leu5] Enkephalin Contributes to Synaptic Improvement in Rat Hippocampus against Global Ischemia.

Authors:  Guangming Zhang; Zelin Lai; Lingling Gu; Kejia Xu; Zhenlu Wang; Yale Duan; Huifen Chen; Min Zhang; Jun Zhang; Zheng Zhao; Shuyan Wang
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.